Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

R pyocin sensitivity of <i>Pseudomonas aeruginosa</i> clinical isolates from different disease types.

Journal of medical microbiology·2026
Same author

Real-Time Detection of Burn Wound Infection via a Turn-On NIR-II Fluorescent Probe.

Chemistry (Weinheim an der Bergstrasse, Germany)·2026
Same author

Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity.

Nature communications·2026
Same author

Lipopolysaccharide-targeting treatments for multidrug-resistant <i>Pseudomonas aeruginosa</i>.

Expert opinion on therapeutic targets·2026
Same author

Feature-Based Molecular Networking Guided Characterization of Clonocoprogen Siderophores with Anti-<i>Pseudomonas aeruginosa</i> Activity in Nematodes through Immune Up-Regulating Effects.

ACS chemical biology·2025
Same author

Box C/D snoRNPs and MDT-15/MED15 regulate mitochondrial surveillance via fatty acid metabolism.

bioRxiv : the preprint server for biology·2025

Related Experiment Video

Updated: May 2, 2026

A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K

High-throughput screening for novel anti-infectives using a C. elegans pathogenesis model.

Annie L Conery1,2, Jonah Larkins-Ford1, Frederick M Ausubel1,2

  • 1Department of Molecular Biology, Massachusetts General Hospital, Boston, Massachusetts.

Current Protocols in Chemical Biology
|March 22, 2014
PubMed
Summary

This study introduces an automated assay using the nematode Caenorhabditis elegans to discover new antimicrobial drugs. This high-throughput screening method identifies compounds effective against Pseudomonas aeruginosa infections.

Keywords:
Caenorhabditis elegansPseudomonas aeruginosaantibioticantimicrobialdrug discoveryhigh-throughput screeningliquid killingpathogenesis model

More Related Videos

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health
11:40

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health

Published on: April 28, 2022

2.8K
Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

20.1K

Related Experiment Videos

Last Updated: May 2, 2026

A High-throughput, High-content, Liquid-based C. elegans Pathosystem
09:44

A High-throughput, High-content, Liquid-based C. elegans Pathosystem

Published on: July 1, 2018

14.2K
High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health
11:40

High-Throughput Screening of Microbial Isolates with Impact on Caenorhabditis elegans Health

Published on: April 28, 2022

2.8K
Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans
10:58

Quantitative and Automated High-throughput Genome-wide RNAi Screens in C. elegans

Published on: February 27, 2012

20.1K

Area of Science:

  • Microbiology
  • Drug Discovery
  • Nematode Biology

Background:

  • Caenorhabditis elegans is a valuable model organism for studying host-pathogen interactions.
  • Pseudomonas aeruginosa is an opportunistic pathogen causing significant human infections.
  • There is a continuous need for novel antimicrobial agents to combat rising antibiotic resistance.

Purpose of the Study:

  • To present an automated, high-throughput screening assay for identifying anti-infective compounds.
  • To utilize Caenorhabditis elegans as a model for drug discovery against Pseudomonas aeruginosa.
  • To enable the identification of novel targets in microbial pathogenesis and host immunity.

Main Methods:

  • Development of a high-throughput screening assay using Caenorhabditis elegans.
  • Infection of nematodes with Pseudomonas aeruginosa.
  • Automated assessment of compound efficacy in preventing nematode mortality.

Main Results:

  • The assay successfully screens for compounds that protect nematodes from P. aeruginosa infection.
  • Identified compounds show potential as novel antimicrobial drugs.
  • The assay facilitates the discovery of new targets in pathogenesis and immunity.

Conclusions:

  • The automated C. elegans assay is an effective platform for discovering new antimicrobial drugs.
  • This screening approach can accelerate the development of treatments for human infections.
  • The assay serves as a tool for probing microbial pathogenesis and host defense mechanisms.